LCTX
Price:
$0.5372
Market Cap:
$118.41M
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevi...[Read more]
Industry
Biotechnology
IPO Date
1992-03-05
Stock Exchange
AMEX
Ticker
LCTX
According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Dividend Yield is 0%. This represents a change of 0% compared to the average of 0% of the last 4 quarters.
The mean historical Dividend Yield of Lineage Cell Therapeutics, Inc. over the last ten years is 2.99%. The current 0% Dividend Yield has changed -100.00% with respect to the historical average. Over the past ten years (40 quarters), LCTX's Dividend Yield was at its highest in in the December 2018 quarter at 29.78%. The Dividend Yield was at its lowest in in the December 2014 quarter at 0%.
Average
2.99%
Median
0%
Minimum
0%
Maximum
29.80%
Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. Dividend Yield, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Dividend Yield = 29.80%
Minimum Annual Increase = 0%
Minimum Annual Dividend Yield = 0%
Year | Dividend Yield | Change |
---|---|---|
2023 | 0% | 0% |
2022 | 0% | 0% |
2021 | 0% | 0% |
2020 | 0% | -100.00% |
2019 | 0.14% | -99.53% |
2018 | 29.80% | Infinity% |
2017 | 0% | 0% |
2016 | 0% | 0% |
2015 | 0% | 0% |
2014 | 0% | 0% |
The current Dividend Yield of Lineage Cell Therapeutics, Inc. (LCTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0%
5-year avg
0.03%
10-year avg
2.99%
Lineage Cell Therapeutics, Inc.’s Dividend Yield is less than MAIA Biotechnology, Inc. (0%), less than Armata Pharmaceuticals, Inc. (0%), less than Frequency Therapeutics, Inc. (0%), less than Portage Biotech Inc. (0%), less than AgeX Therapeutics, Inc. (0%), less than Cadrenal Therapeutics, Inc. Common Stock (0%), less than ImmuCell Corporation (0%), less than Oxford Nanopore Technologies plc (0%), less than Replimune Group, Inc. (0%), less than Nuvectis Pharma, Inc. (0%), less than Lyra Therapeutics, Inc. (0%), less than Kronos Bio, Inc. (0%), less than Gossamer Bio, Inc. (0%), less than Neoleukin Therapeutics, Inc. (0%), less than Nuvation Bio Inc. (0%), less than Ovid Therapeutics Inc. (0%), less than NextCure, Inc. (0%), less than Connect Biopharma Holdings Limited (0%), less than Spero Therapeutics, Inc. (0%), less than Bolt Biotherapeutics, Inc. (0%), less than Coherus BioSciences, Inc. (0%), less than Gracell Biotechnologies Inc. (0%),
Company | Dividend Yield | Market cap |
---|---|---|
0% | $50.41M | |
0% | $73.82M | |
0% | $10.94M | |
0% | $5.82M | |
0% | $27.76M | |
0% | $24.50M | |
0% | $41.08M | |
0% | $1.59B | |
0% | $941.76M | |
0% | $89.84M | |
0% | $11.28M | |
0% | $57.32M | |
0% | $191.23M | |
0% | $8.20M | |
0% | $949.12M | |
0% | $68.62M | |
0% | $24.31M | |
0% | $55.03M | |
0% | $51.11M | |
0% | $19.63M | |
0% | $169.36M | |
0% | $989.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Dividend Yield?
How can you use the Dividend Yield?
What is Lineage Cell Therapeutics, Inc.'s Dividend Yield?
How is the Dividend Yield calculated for Lineage Cell Therapeutics, Inc. (LCTX)?
What is the highest Dividend Yield for Lineage Cell Therapeutics, Inc. (LCTX)?
What is the 3-year average Dividend Yield for Lineage Cell Therapeutics, Inc. (LCTX)?
What is the 5-year average Dividend Yield for Lineage Cell Therapeutics, Inc. (LCTX)?
How does the current Dividend Yield for Lineage Cell Therapeutics, Inc. (LCTX) compare to its historical average?